Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1

Abstract

These data demonstrate that single observed endpoints are not appropriate to determine efficacy, partly accounting for the poor test-retest reliability of cognitive outcomes in clinical trials in neurodevelopmental disorders. Recommendations to improve reproducibility are outlined to guide future trial design.